A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection.

Trial Profile

A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2016

At a glance

  • Drugs Vapendavir (Primary)
  • Indications Asthma; Rhinovirus infections
  • Focus Therapeutic Use
  • Acronyms RHINO
  • Sponsors Biota Pharmaceuticals
  • Most Recent Events

    • 08 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
    • 28 Mar 2012 Primary endpoint 'Wisconsin-Upper-Respiratory-Symptom-Survey' has been met, according to a Biota Holdings media release.
    • 28 Mar 2012 Status changed from active, no longer recruiting to completed, according to a Biota Holdings media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top